Order byBest matchMost fresh
MassDevice2h
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025
Daily Voice on MSN5h
Westchester-Based Regeneron Buying Bankrupt 23andMe For $256M, Pledges To Protect DNA Data
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services with no changes.
Regeneron Pharmaceuticals (NasdaqGS:REGN) Partners With Viz.ai For AI-Powered COPD Solutions
Viz.ai's recent partnership with Sanofi and Regeneron Pharmaceuticals (NasdaqGS:REGN) brings AI technology to aid in the management of COPD patients, enhancing the healthcare process. Throughout the past month,
JD Supra1h
Regeneron Awarded $407 Million in Amgen Antitrust Suit
On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals,
Pharmaceutical Technology3h
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of control before randomisation.
Explore more
Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ: SNY), an innovative global healthcare company, and Regeneron (NASDAQ: REGN),
Feedback